PI3K/Akt/mTOR信号转导通路与非小细胞肺癌

Lung cancer is one of the leading causes of cancer-related deaths worldwide and non-small cell lung cancer (NSCLC) accounts for about 75%-85% of all lung cancers. NSCLC often presents at stages too late for surgical intervention and traditional treatments including chemotherapy and radiotherapy are inadequate. The 5-year survival rate of NSCLC is only 5%-10%. PI3K/Akt/mTOR signaling pathway is an important intracellular signal transduction pathway. It plays an important role in cell apoptosis and survival by affecting the activity of downstream effector molecules, and it is closely associated with the development and progression of NSCLC. This article reviewed recent progress on the composition, anti-apoptosis and pro- proliferation of PI3K/Akt/mTOR signaling pathway, and discussed its potential targets to NSCLC therapy.